Inappropriate ICD Therapy Due to Proarrhythmic ICD Shocks and Hyperpolarization

Influence of myopotential interference on the Wavelet discrimination algorithm in implantable cardioverter-defibrillator

Background

Wavelet is a morphology-based algorithm for detecting ventricular tachycardia. The electrogram (EGM) source of the Wavelet algorithm is nominally programmed with the Can-RV coil configuration, which records a far-field ventricular potential. Therefore, it may be influenced by myopotential interference.

Methods

We performed a retrospective review of 40 outpatients who had an implantable cardioverter-defibrillator (ICD) with the Wavelet algorithm. The percent-match score of the Wavelet algorithm was measured during the isometric chest press by pressing the palms together. We classified patients with percent-match scores below 70% due to myopotential interference as positive morphology change, and those with 70% or more as negative morphology change. Stored episodes of tachycardia were evaluated during the follow-up.

Results

The number of patients in the positive morphology change group was 22 (55%). Amplitude of the Can-RV coil EGM was lower in the positive morphology change group compared to that in the negative group (3.9±1.3 mV vs. 7.4±1.6 mV, P=0.0015). The cut-off value of the Can-RV coil EGM was 5 mV (area under curve, 0.89). Inappropriate detections caused by myopotential interference occurred in two patients (5%) during a mean follow-up period of 49 months, and one of them received an inappropriate ICD shock. These patients had exhibited positive morphology change.

Conclusions

The Wavelet algorithm is influenced by myopotential interference when the Can-RV coil EGM is less than 5 mV.

Lower incidence of inappropriate shock therapy in patients with combined cardiac resynchronisation therapy defibrillators (CRT-D) compared with patients with non-CRT defibrillators (ICDs)

INTRODUCTION

A significant number of patients experience inappropriate shock therapy (IST) from implantable cardioverter-defibrillators (ICD). An increasing number of patients with advanced heart failure receive combined ICD and cardiac resynchronisation therapy devices (CRT-D). The incidence of IST in this group is less well described. We aimed to assess the incidence and predictors of IST in CRT-D patients.

METHODS

A retrospective cohort study of prospectively collected data on patients who received an ICD and CRT-D between October 2007 and January 2009 at our institution were studied. The primary outcome measures were the IST event rate and all-cause mortality.

RESULTS

A total of 185 patients with ICD/CRT-D (100/85) were included in the analysis. Eighteen patients experienced 35 episodes of IST during the follow-up (21 ± 13 months). There was a significantly lower IST cumulative event rate in the CRT-D vs. ICD group, 5% (CI: 1-13%) vs. 19% (95% CI: 11-30%) by 24 months, (p = 0.017). The majority of the IST was caused by atrial arrhythmias with atrial fibrillation accounting for 28 episodes of IST in nine patients. Multivariate analysis using Cox hazard model including baseline characteristics and coexisting appropriate shock therapy showed that a history of atrial fibrillation/flutter was the strongest independent predictor of IST with a hazard ratio of 3.53 (p = 0.019).

CONCLUSION

Patients with CRT-D had a significantly lower incidence of IST compared with patients receiving an ICD. Given that atrial arrhythmia remained the commonest trigger for IST, our finding lends support to the hypothesis that CRT may reduce atrial fibrillation burden in patients receiving CRT-D.

Innovative P-wave detection for discrimination between ventricular and supraventricular tachycardia in single-chamber ICDs: is the P-wave invisible during tachycardia?

AIMS

Differentiation between supraventricular tachycardia (SVT) and ventricular tachycardia (VT) remains a substantial clinical challenge in patients with single-chamber implantable cardioverter-defibrillators (ICDs) due to absence of visible P waves. Innovative optimization of intrathoracic electrogram (EGM) configuration will facilitate P-wave detection and rhythm differentiation during tachycardia.

METHODS AND RESULTS

Innovative optimization of EGM configuration was originally performed to improve patient care. In this retrospective cohort study, we examined our database for records of 140 consecutive patients undergoing single-chamber ICD implantation. During the follow-ups of 61 included patients with optimized EGM configuration, 27 patients were identified to have VT and/or SVT. EGMs in the Can (generator) to superior vena cava (Can-SVC) configuration were compared with those conventionally from the Can to right ventricular coil (Can-RV coil) source in the same patients. In Can-SVC EGMs, the ratio of P/QRS amplitude was 14-fold higher (0.57 ± 0.08 vs. 0.04 ± 0.00, P < 0.001) compared with those in Can-RV coil EGMs during sinus rhythm. With Can-SVC configuration, the odds of atrioventricular dissociation detection in patients with VT was increased 15-fold (61.9% vs. 9.5% with Can-RV coil; odds ratio, 15.4; 95% confidence interval, 2.8 to 84.7; P = 0.0009). In patients with SVT, P-waves or retrograde P-waves were markedly more identifiable in Can-SVC configuration compared with Can-RV coil (odds ratio, 40; 95% confidence interval, 3.6 to 447.1; P = 0.0010).

CONCLUSION

P-wave recognition by optimizing EGM configuration provides a novel diagnostic tool for differentiation between VT and SVT in single-chamber ICDs. A potential discrimination algorithm would provide a cost-effective approach to improving the qualitative outcomes.

Delayed and indirect effects of antiarrhythmic drugs in reducing sudden cardiac death

In the USA, two-thirds of sudden cardiac deaths (SCDs) are caused by sustained ventricular tachycardia and ventricular fibrillation. Implantable cardioverter defibrillator (ICD) therapy has been demonstrated to decrease mortality caused by these arrhythmias, when used both for primary and secondary prevention. However, ICD use is expensive, has proarrhythmic effects and does not prevent ventricular arrhythmias. Antiarrhythmic drugs (AADs) can be used for acute or chronic therapy to prevent ventricular arrhythmias and SCD. Most commonly, AADs are often used in patients with an ICD who have recurrent ICD shocks due to ventricular arrhythmias. Class I AADs are used in patients with a structurally normal heart and are contraindicated in patients with structural heart disease. β-blockers have been demonstrated to be beneficial in preventing mortality and malignant tachyarrhythmias in postmyocardial infarction and congestive heart failure patients, and in patients who have an ICD. Amiodarone has a neutral effect on mortality, while other class III drugs may increase mortality in certain subgroups of patients. Dronedarone, a new class III drug, may reduce mortality, but sufficient data are not available to allow for its use in the prevention of malignant tachyarrhythmias. Few drugs that are not classified as AADs can also prevent arrhythmias, via their beneficial effects on cardiovascular remodeling. These non-ADDs have delayed and indirect effects, which are mediated by the renin-angiotensin-aldosterone system and lipid metabolism - n-3 polyunsaturated fatty acids (fish oil), and statins, and can thus can reduce the likelihood of future malignant ventricular arrhythmias in patients with coronary artery disease or congestive heart failure. The role of chronic drug therapy alone for primary and secondary prevention of SCD is less than desirable because of proarrhythmic and adverse side effects. The non-ADDs are well tolerated and have no proarrhythmic actions, thus their benefit could outweigh risks, although currently there are no concrete data to suggest this.

Implantable Cardioverter-Defibrillator Therapy for Primary Prevention of Sudden Cardiac Death: An Argument for Restraint

Although it is estimated that a total of 220,000 patients undergo implantable cardioverter-defibrillator (ICD) implantation per year, only 10% to 20% of these patients experience life-saving therapy; this leaves up to 90% of the targeted population as "nonresponders," who do not derive clinical benefit but incur all of the risks from ICD implantation. This article reviews the landmark primary prevention trials to assess the incidence of sudden death and the absolute magnitude of benefit derived from ICD therapy. The discrepancy between trial patients and real-world implementation of ICD therapy is examined, and the potential for risks incurred from ICD implantation is presented. The natural history of patients who receive appropriate ICD therapy and the durability of ICD benefit with respect to cost-effective analyses are discussed, to support the authors' position that ICD therapy should not be routinely used for the primary prevention of sudden cardiac death.

Tools and strategies for the reduction of inappropriate implantable cardioverter defibrillator shocks

Implantable cardioverter defibrillators (ICDs) have been shown to provide a survival benefit in patients at high risk of sudden cardiac death. A major problem associated with ICD therapy is the occurrence of inappropriate shocks which impair patients' quality of life and may also be arrhythmogenic. Despite recent technological advances, the incidence of inappropriate shocks remains high, thus posing a challenge that we have to meet. In the present review we summarise the available tools and the strategies that can be followed in order to reduce inappropriate ICD shocks.

Necessity for surgical revision of defibrillator leads implanted long-term: causes and management

BACKGROUND

Defibrillator lead malfunction is a potential long-term complication in patients with an implantable cardioverter-defibrillator (ICD). The aim of this study was to determine the incidence and causes of lead malfunction necessitating surgical revision and to evaluate 2 approaches to treat lead malfunction.

METHODS AND RESULTS

We included 1317 consecutive patients with an ICD implanted at 3 European centers between 1993 and 2004. The types and causes of lead malfunction were recorded. If the integrity of the high-voltage part of the lead could be ascertained, an additional pace/sense lead was implanted. Otherwise, the patients received a new ICD lead. Of the 1317 patients, 38 experienced lead malfunction requiring surgical revision and 315 died during a median follow-up of 6.4 years. At 5 years, the cumulative incidence was 2.5% (95% confidence interval, 1.5 to 3.6). Lead malfunction resulted in inappropriate ICD therapies in 76% of the cases. Implantation of a pace/sense lead was feasible in 63%. Both lead revision strategies were similar with regard to lead malfunction recurrence (P=0.8). However, the cumulative incidence of recurrence was high (20% at 5 years; 95% confidence interval, 1.7 to 37.7).

CONCLUSIONS

ICD lead malfunction necessitating surgical revision becomes a clinically relevant problem in 2.5% of ICD recipients within 5 years. In selected cases, simple implantation of an additional pace/sense lead is feasible. Regardless of the chosen approach, the incidence of recurrent ICD lead-related problems after lead revision is 8-fold higher in this population.

Improving SVT Discrimination in Single-Chamber ICDs: A New Electrogram Morphology-Based Algorithm

INTRODUCTION

Wide-spread adoption of ICD therapy has focused efforts on improving the quality of life for patients by reducing "inappropriate" shock therapies. To this end, distinguishing supraventricular tachycardia from ventricular tachycardia remains a major challenge for ICDs. More sophisticated discrimination algorithms based on ventricular electrogram morphology have been made practicable by the increased computational ability of modern ICDs.

METHODS AND RESULTS

We report results from a large prospective study (1,122 pts) of a new ventricular electrogram morphology tachycardia discrimination algorithm (Wavelet Dynamic Discrimination, Medtronic, Minneapolis, MN, USA) operating at minimal algorithm setting (RV coil-can electrogram, match threshold of 70%). This is a nonrandomized cohort study of ICD patients using the morphology discrimination of the Wavelet algorithm to distinguish SVT and VT/VF. The Wavelet criterion was required ON in all patients and all other supraventricular tachycardia discriminators were required to be OFF. Spontaneous episodes (N = 2,235) eligible for ICD therapy were adjudicated for detection algorithm performance. The generalized estimating equations method was used to remove bias introduced when an individual patient contributes multiple episodes. Inappropriate therapies for supraventricular tachycardia were reduced by 78% (90% CI: 72.8-82.9%) for episodes within the range of rates where Wavelet was programmed to discriminate. Sensitivity for sustained ventricular tachycardia was 98.6% (90% CI: 97-99.3%) without the use of high-rate time out.

CONCLUSIONS

Results from this prospective study of the Wavelet electrogram morphology discrimination algorithm operating as the sole discriminator in the ON mode demonstrate that inappropriate therapy for supraventricular tachycardia in a single-chamber ICD can be dramatically reduced compared to rate detection alone.